Lightnews — Scholar-powered news

Ilana Schlam

@ilanaschlam.bsky.social

320 followers 92 following 10 posts

Breast medical oncologist @Dana-Farber | Harvard | Posts are my own and not medical advise

Posts Media Videos Starter Packs

Pinned

Ilana Schlam @ilanaschlam.bsky.social · Nov 17

Updated treatment algorithms for breast cancer now include adjuvant ribociclib and inavolisib, along with key trial names. Thrilled to see we're truly running out of space in HR+ disease—progress is here, with much more to come for all breast cancer subtypes!

3 16 71

Ilana Schlam @ilanaschlam.bsky.social · Feb 18

These are the most recent ones :)

Reposted by Ilana Schlam

Elisabetta Bonzano MD, PhD @elisabettabonzano.bsky.social · Jan 19

📌 Tumor-infiltrating lymphocytes in HER2-positive breast cancer: potential impact and challenges
👉🏻 sciencedirect.com/science/articl…
@ilanaschlam.bsky.social @loisher.bsky.social
@oncoalert.bsky.social

4 5

Reposted by Ilana Schlam

Dana-Farber’s Breast Oncology Center @dfcibreastonc.bsky.social · Jan 15

Don't miss this recent review outlining practical treatment strategies and novel therapies in the PI3K/AKT/mTOR pathway in HR+/HER2- advanced #BreastCancer
🔓 pubmed.ncbi.nlm.nih.gov/39674130/
@antgiordanomd.bsky.social @drtimothyerick.bsky.social @stolaney1.bsky.social @drsarahsammons.bsky.social

6 12

Reposted by Ilana Schlam

Hidehito HORINOUCHI @hhorinouchi.bsky.social · Jan 4

🔥Nature Medicine🆙
✅Evaluating generalizability of oncology trial results to real-world pts using machine learning-based trial emulations
🎯Decision support/estimation of RW treatment benefit
👥Drs. Xavier Orcutt, Ravi B. Parikh et al.
#LCSM @oncoalert.bsky.social #AI
www.nature.com/articles/s41...

Evaluating generalizability of oncology trial results to real-world patients using machine learning-based trial emulations - Nature Medicine

Machine-learning-based and population-level electronic health record data–based emulation of landmark phase 3 randomized controlled trials (RCTs) in oncology across a range of cancer and risk types sh...

www.nature.com

5 11

Ilana Schlam @ilanaschlam.bsky.social · Dec 20

@stolaney1.bsky.social @dfcibreastonc.bsky.social

Ilana Schlam @ilanaschlam.bsky.social · Dec 20

The BRIDGES study @JCO GO

❓ Management of IBC in low and middle income countries
✅ 112 responses from clinicians from 36 counties
🔑 1/3 of patients with non metastatic IBC are receiving TMT
🔑 provider education everywhere is key to improve patient outcomes

ascopubs.org/doi/pdf/10.1...

1 3 6

Reposted by Ilana Schlam

Sarah Sammons MD @drsarahsammons.bsky.social · Dec 11

RLY2608 is a mutant specific PIK3CA inhibitor sparing Wildtype Receptor.

2nd line PFS >11 months with fulvestrant.

Improved safety profile with low grade hyperglycemia, no rash, diarrhea, or oral sores.

Hoping this one moves forward!

#SABCS24 @oncoalert.bsky.social @oncbrothers.bsky.social

2 11 22

Reposted by Ilana Schlam

Yüksel Ürün @yukselurun.bsky.social · Dec 17

🩸🧬Exciting update!
LB-RECIST introduces a new era for evaluating tumor response using liquid biopsy addressing limits of imaging in solid tumors. A step toward precision oncology!
@oncoalert.bsky.social
@christianrolfo.bsky.social
@viveksubbiah.bsky.social
www.annalsofoncology.org/action/showP...

1 4 16

Ilana Schlam @ilanaschlam.bsky.social · Dec 13

Wrapping up another fantastic #SABCS!

Amazing, practice-changing data were presented.

I’ve updated the algorithms and added key studies from the meeting— I finally ran out of space in HR+ disease!

#SABCS24 @oncoalert.bsky.social

19 45

Reposted by Ilana Schlam

Erika Hamilton MD, FASCO @erikahamilton9.bsky.social · Dec 13

Dr. Turner presents #ZEST adj study of MRD in pts with HR + w/ BRCA & TNBC all comers w/ niraparib as intervention

147 had ctDNA+, only 40 randomized

Rad recurrence assoc w/ ⬆️ ctDNA level

RFI 5.4 -> 11.4 mo w/ niraparib

#SABCS24
@sabcs.bsky.social
@oncoalert.bsky.social

1 5 14

Ilana Schlam @ilanaschlam.bsky.social · Dec 12

PRACTICE CHANGING findings from PATINA presented by Dr. Metzger from @dfcibreastonc.bsky.social
- n=518 HR+/HER2+ mBC
- all received THP followed by HP+ET +/- palbo
- PFS was 29 vs 44 months with palbo
- Tox consistent with prior studies

2 13

Ilana Schlam @ilanaschlam.bsky.social · Dec 12

Great discussion of novel biomarkers and HER2-targeted TKIs by @ptarantinomd.bsky.social @dfcibreastonc.bsky.social

2 9

Ilana Schlam @ilanaschlam.bsky.social · Dec 11

Stellar discussion by Dr Burstein
on the important findings of EMBER-3 presented by
Dr Jhaveri

Some important clinical questions:
❓how to incorporate these findings in clinic - with the approval of inavo-?
❓are we ready for ADC post ADC?
❓how to sequence these agents?

Reposted by Ilana Schlam

Erika Hamilton MD, FASCO @erikahamilton9.bsky.social · Dec 11

#EMBER3

Imlunestrant (oral SERD) beats fulv (88% of SOC ET) in 2nd line ER+ #bcsm only in those with ESR1 mut

However, combo of Imlunestrant + abema wins in all-comers 5.5 vs. 9.5 mo regardless of ESR1

* note prior CDK not required

#SABCS24
@sabcs.bsky.social
@oncoalert.bsky.social

6 22

Reposted by Ilana Schlam

Paolo Tarantino, MD @ptarantinomd.bsky.social · Dec 11

Outstanding spotlight poster discussion by Thomas Grinda from Gustave Roussy. Promising results with the 1L combination of chemo, IO and VEGF blockade for mTNBC. Will the inclusion of IO in the combo change the story of VEGF, previously thought not to improve long-term outcomes for breast cancer?

4 13

Reposted by Ilana Schlam

Sarah Sammons MD @drsarahsammons.bsky.social · Dec 11

Practice change ALERT in the POST-CDK4/6 HR+, HER2- space.

NEJM.org @nejm.org · Dec 11

The selective estrogen-receptor degrader imlunestrant plus abemaciclib led to a median progression-free survival of 9.4 months among patients with ER-positive, HER2-negative breast cancer (vs. 5.5 months with imlunestrant alone). Full EMBER-3 trial results: nej.md/4fZ74HX

#MedSky #SABCS24

Kaplan–Meier estimates of progression-free survival among all 426 patients in the imlunestrant–abemaciclib and imlunestrant groups who had undergone randomization concurrently.

5 10

Reposted by Ilana Schlam

OncLive @onclive.bsky.social · Dec 10

We're kicking off the first day of our LIVE coverage of #SABCS24 with expert insights from @ilanaschlam.bsky.social of @danafarber.bsky.social, who will be taking over the @OncLive X and Bluesky🦋 accounts to cover this evening's sessions! Be sure to tune in! @sabcs.bsky.social #bcsm #oncology

2 6

Ilana Schlam @ilanaschlam.bsky.social · Dec 10

The ASCO virtual mentoring program (VMP) is now accepting applications; this is a great opportunity for trainees. This program was career-changing for me. Consider applying!

@stolaney1.bsky.social @dfcibreastonc.bsky.social

asco.smapply.org/prog/2025-26...

2025-26 ASCO Virtual Mentoring Program - Application Portal

asco.smapply.org

Reposted by Ilana Schlam

Sarah Sammons MD @drsarahsammons.bsky.social · Dec 9

I created a SABCS Breast Thought Leader Starter Pack for anyone new to @bsky.app and following @sabcs.bsky.social

Will try to add all thought leaders as I go!

go.bsky.app/MkqBYa7

11 9 29

Reposted by Ilana Schlam

Dana-Farber’s Breast Oncology Center @dfcibreastonc.bsky.social · Dec 9

Here’s the #BreastCancer Research Digest - a summary of last week’s publications from select high-impact journals (December 2nd-8th, 2024). #ClinicalResearch #CancerTreatment #BCSM #BreastCancerResearch

4 3

Reposted by Ilana Schlam

Dana-Farber’s Breast Oncology Center @dfcibreastonc.bsky.social · Dec 6

Check out this recent review on the role of #AntibodyDrugConjugates in the treatment of patients with #BreastCancerBrainMetastases.
pubmed.ncbi.nlm.nih.gov/39529890/
#StaceyPan @drsarahsammons.bsky.social @nlinmd.bsky.social @stolaney1.bsky.social @ilanaschlam.bsky.social @ptarantinomd.bsky.social

1 10 11

Reposted by Ilana Schlam

Paolo Tarantino, MD @ptarantinomd.bsky.social · Dec 6

Make sure to follow @dfcibreastonc.bsky.social for updates on the latest research efforts by DFCI BOC and for periodic research digest with recent news in breast oncology! @stolaney1.bsky.social

1 7 16

Reposted by Ilana Schlam

Jarushka Naidoo @drjnaidoo.bsky.social · Nov 29

Impact of cycle 1 irAEs on ICI outcomes:
- 683pts from SWOG DART trial
- g1-2 irAEs = ⬆️OS HR 0.61 p < 0.001
- g3+ irAEs = ⬇️OS HR 1.41 p= .025
- g1-2 derm irAE = ⬆️OS v other g1-2 irAE HR 0.67 p=0.002

Congrats @eladsharonmd.bsky.social @oncoalert.bsky.social

academic.oup.com/jnci/advance...

First Cycle Toxicity and Survival in Patients with Rare Cancers Treated with Checkpoint Inhibitors

AbstractBackground. Associations between immune-related adverse events (irAEs) from checkpoint inhibitor therapy and outcomes have been previously evaluate

academic.oup.com

15 27

Ilana Schlam @ilanaschlam.bsky.social · Nov 27

Looking forward to #SABCS24 - there is a lot of important research being presented, some to highlight:
🔑 Biomarker analysis of KN522
🔑 EMBER-3
🔑 MARGOT
🔑 SONIA
🔑 EUROPA
🔑 SOLTI VALENTINE
🔑 GeparDouze

4 14

Reposted by Ilana Schlam

Paolo Tarantino, MD @ptarantinomd.bsky.social · Nov 25

Regular abstracts from #SABCS24 are out!

3407 pages of new breast cancer discoveries.

Find them here: sabcs.org/Portals/0/Do...

sabcs.org

15 62